Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Cell Therapy Group
Shanghai, Shanghai, China
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Shanghai Cell Therapy Group is actively developing CAR-T cell therapies targeting solid and hematologic tumors, with their lead Phase 1 program BZDS-1901 targeting mesothelin-positive neoplasms. They are also progressing glioma cell therapy preclinically and conducting translational research in hematopoietic stem cell expansion and modification. Clinical efficacy data is early stage.
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapyCAR-T cell therapyMonoclonal antibody
- Industry
- Biotech
02
Partnerships
University of Southern California (USC), Keck School of Medicine (hematopoietic stem cell expansion collaboration)
Beyond the preview
Go deeper on Shanghai Cell Therapy Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Cell Therapy Group.